Angiogenesis and antiangiogenic therapy in hematologic malignancies.
about
Second-generation taxanes effectively suppress subcutaneous rat lymphoma: role of disposition, transport, metabolism, in vitro potency and expression of angiogenesis genesTumor angiogenesisAnticancer Role of PPARgamma Agonists in Hematological Malignancies Found in the Vasculature, Marrow, and Eyes.Vascular endothelial growth factor-related pathways in hemato-lymphoid malignancies.Plant proteolytic enzyme papain abrogates angiogenic activation of human umbilical vein endothelial cells (HUVEC) in vitro.What role for angiogenesis in childhood acute lymphoblastic leukaemia?Phase II study of 'high-dose' celecoxib and metronomic 'low-dose' cyclophosphamide and methotrexate in patients with relapsed and refractory lymphoma.Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategiesHalofuginone inhibits phosphorylation of SMAD-2 reducing angiogenesis and leukemia burden in an acute promyelocytic leukemia mouse model.Adding to the mix: fibroblast growth factor and platelet-derived growth factor receptor pathways as targets in non-small cell lung cancerEGF-Induced VEGF Exerts a PI3K-Dependent Positive Feedback on ERK and AKT through VEGFR2 in Hematological In Vitro Models.Thalidomide and irradiation combination therapy increases substance P levels in vitroPeroxisome Proliferator-Activated Receptor-gamma Ligands: Potential Pharmacological Agents for Targeting the Angiogenesis Signaling Cascade in Cancer.Clinical trials with anti-angiogenic agents in hematological malignancies.Targeting the vascular endothelial growth factor in hematologic malignancies.Angiogenesis and proliferation index in patients with acute leukemia: a prospective studyChallenges in vaccine therapy in hematological malignancies and strategies to overcome them.Heparan sulfate D-glucosaminyl 3-O-sulfotransferase-3B1 (HS3ST3B1) promotes angiogenesis and proliferation by induction of VEGF in acute myeloid leukemia cells.Bone marrow micro-environment is a crucial player for myelomagenesis and disease progression.3,4-Dimethoxystilbene, a resveratrol derivative with anti-angiogenic effect, induces both macroautophagy and apoptosis in endothelial cells.Antiangiogenic activity of berberine is mediated through the downregulation of hypoxia-inducible factor-1, VEGF, and proinflammatory mediators.VEGFR2-targeted fusion antibody improved NK cell-mediated immunosurveillance against K562 cells.Angiogenesis in myeloproliferative neoplasms, new markers and future directions.Does serum soluble vascular endothelial growth factor levels have different importance in pediatric acute leukemia and malignant lymphoma patients?The significance of non correlation between interleukin-8 serum levels with bone marrow microvascular density in patients with myeloma multiple.Identification of noreremophilane-based inhibitors of angiogenesis using zebrafish assays.Targeting vasculogenesis to prevent progression in multiple myeloma.
P2860
Q28574018-E455DA15-5507-4DAB-A86B-9FA4800DB8A2Q29614938-6C7EE423-8B16-4B86-8930-3AF93968E7B5Q33692555-87316D92-5CCA-47C4-8800-3A286120887BQ33874179-44B27DF3-21C1-443B-AA36-BAF395035855Q34992804-0C9FCA56-6EF7-480A-B07A-88E673D2BB6AQ35550914-AFEE53F7-EC3C-445B-A0C9-B3E0DB0708C6Q35572896-C273C4BF-6AF9-483E-AB40-36E8C4036491Q35584182-411ABCE3-73E3-4FA9-89AE-5481C986556EQ35800540-DA7599B8-DD67-4246-A6D9-7326F4CA6DEAQ36161541-1EBF5E19-D6F3-4D5A-84E8-6AB8D735299CQ36180362-CE5D5E6D-F2FF-4AF1-946A-00A0B4F426CAQ36230673-06BDF3A4-4D6A-4C4E-8D95-693EB9C10C88Q37157524-D7D4458E-5B91-4FC8-A902-BC6AC8F8A154Q37766940-0674829B-82E8-4ED3-93F1-BB0B6532D7C2Q38038645-6ACA2F71-8BF9-485A-BF06-C221CB7D16BFQ38784730-8B1BB9E3-0C1D-4C73-BE44-F2AED5C44AAEQ38843235-71071785-9380-4CC9-B10C-8F6DB0E6E8D5Q38925857-41AC3D9D-037B-48F4-B693-11613C851CA5Q39093915-074DC792-F57D-4D21-85CC-FBC2333F745EQ39260937-4F0E0308-3970-4445-ADE4-295ABC135164Q39432387-7E37263E-F8DF-458C-8750-3FA8B9511568Q39787455-AAB1BF6B-E1CD-41DE-A006-88C3CBE5F462Q42622713-8E947684-5938-47F1-8779-432AAC1E9D48Q46193990-E9AF24D6-DFB9-460B-A5C7-C59C60889BC7Q46554858-1F9C0C0A-CB87-4915-B208-EDA80BEFC034Q46651693-CB6D89EA-00CE-4926-955C-C8A438C1E968Q52885536-AF4E1F28-DE55-459E-A844-A7CB769D5FB7
P2860
Angiogenesis and antiangiogenic therapy in hematologic malignancies.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Angiogenesis and antiangiogenic therapy in hematologic malignancies.
@ast
Angiogenesis and antiangiogenic therapy in hematologic malignancies.
@en
type
label
Angiogenesis and antiangiogenic therapy in hematologic malignancies.
@ast
Angiogenesis and antiangiogenic therapy in hematologic malignancies.
@en
prefLabel
Angiogenesis and antiangiogenic therapy in hematologic malignancies.
@ast
Angiogenesis and antiangiogenic therapy in hematologic malignancies.
@en
P1476
Angiogenesis and antiangiogenic therapy in hematologic malignancies
@en
P2093
Renchi Yang
Xunwei Dong
P304
P356
10.1016/J.CRITREVONC.2006.11.006
P577
2006-12-22T00:00:00Z